The Comparison Of Use Of Tacrolimus In Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation

Objective: To discuss the difference of safety and efficacy of tacrolimus asimmunosuppressor in allogeneic peripheral blood hematopoietic stem cell transplantation.Method: The research object is65patients from January2009to March2012amongallo-SCT recipients. With male43and female22,divided into tacrolimus group andCyclosporin A group. tacrolimus-based immunosuppression for graft-versus-host disease(GVHD) prophylaxis is in one group,the other is based on Cyclosporin A.The rest of isindifference between the two groups.Result: the effective number of FK506group is27while CsA group is38. The cumulateincident of aGVHD and cGVHD is28.6%,55.6%and24.3%,31.58%, respectively. Thereis no significantly difference between aGVHD and cGVHD (p>0.05). The recurrence rateand mortality of them are similar(p>0.05).The major cause of death is relapse.The adversereaction of these two drug are similar,except for hyperglycemia(p<0.05).Conclution: The incidence of acute and chronic GVHD in the two groups has nodifference,the recurrence rate and mortality rate have no obvious difference afterhematopoietic stem cell transplantation.Tacrolimus also has the adverse effects such ashyperglycemia,hypertension,damage of renal and nervous system, etc, but they are allunder control. These results suggest that tacrolimus may have a role in patients afterallogeneic marrow transplantation,especially for patients who Cannot tolerate otherimmunosuppressor.